Development of Reversed-Phase Methods for the Analysis of Biotherapeutic Synthetic Peptides including GLP-1 Agonists
The use of biotherapeutic synthetic peptides in drug development has grown significantly in the past decade.
Biotherapeutic synthetic peptides often have higher efficacy, safety, and tolerability in humans compared to small molecules. They also have lower production complexity and cost than protein-based biopharmaceuticals.
While synthesis reactions are carefully controlled, impurities as well as degradation species are inevitably formed and must be characterized and identified. Having a robust Reversed-Phase (RP) method provides a solid foundation in the characterization and identification of these impurities.
This webinar will review some of the principles and practices to develop robust RP separation methods showing examples using GLP-1 Agonists.
- Principles of Reversed-Phase LC and LC/MS of Peptides
- Considerations in Selecting an Appropriate RP Column
- Considerations in Selecting an Appropriate RP Eluent
- Step by Step Approach to Developing a Robust Peptide Separations
Presenter: Bill Warren (Principal Consultant Product Manager, Waters Corporation)
In 1986, Bill joined Waters Corporation as a senior applications chemist involved with the research and development of HPLC, FPLC, and Capillary Electrophoresis applications for the analysis and purification of proteins, peptides, and nucleic acids.
He currently is a Principal Consulting Bio separations Product Manager whose responsibilities involve assisting in the development and commercialization of innovative reagents and chromatography-based technologies for the separation, purification, and characterization of proteins and peptides.
